Results 31 to 40 of about 3,395 (155)

Intrinsic Motivation [PDF]

, 2014
Employs a literature review to describe intrinsic motivation as the force behind pro-social behavior, or when individuals willingly engage in behavior that is costly to them but benefits others.
Brock, J. Michelle, Leonard, Kenneth L., Serneels, Pieter   +2 more
core   +1 more source

Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk [PDF]

, 2016
Control of lipid levels is one of the most effective strategies for cardiovascular (CV) event prevention. In fact, many clinical trials have clearly demonstrated that low-density lipoprotein cholesterol (LDL-C) lowering, primarily with statins, reduces ...
AGABITI ROSEI, Enrico, SALVETTI, Massimo
core   +1 more source

Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes:A systematic review and meta-analysis [PDF]

, 2019
Background: To evaluate the effects of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors on major adverse cardiovascular events (MACE).Methods: Our systematic review included randomised controlled trials if they studied PCSK9 inhibitors in ...
Du, Heyue, Gao, Haihui, Hao, Xiaoting, Kwong, Joey S. W., Lang, Chim, Li, Jianshu, Li, Ling, Li, Qianrui, Li, Sheyu, Li, Xiaodan, Mordi, Ify, Nemeth, Imola, Rao, Li, Su, Na, Tian, Haoming, Vandvik, Per Olav, Yang, Xueli, Zhang, Longhao   +17 more
core   +3 more sources

Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography

Lipids in Health and Disease, 2021
Background Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors have been demonstrated to produce significantly greater reduction in LDL cholesterol levels and cardiovascular events than standard statin therapy.
Fei Gao, Zhi Jian Wang, Xiao Teng Ma, Hua Shen, Li Xia Yang, Yu Jie Zhou   +5 more
doaj   +1 more source

Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis

Critical Care Explorations, 2023
OBJECTIVES:. Treatments that prevent sepsis complications are needed. Circulating lipid and protein assemblies—lipoproteins play critical roles in clearing pathogens from the bloodstream.
Patrick R. Lawler, MD, MPH, Garen Manvelian, PhD, Alida Coppi, PhD, Amy Damask, PhD, Michael N. Cantor, MD, Manuel A. R. Ferreira, PhD, Charles Paulding, PhD, Nilanjana Banerjee, PhD, Dadong Li, PhD, Susan Jorgensen, MS, Richa Attre, PhD, David J. Carey, PhD, Kristi Krebs, PhD, Lili Milani, PhD, Kristian Hveem, MD, Jan K. Damås, PhD, Erik Solligård, PhD, Stefan Stender, MD, Anne Tybjærg-Hansen, MD, Børge G. Nordestgaard, MD, Tamara Hernandez-Beeftink, PhD, Tormod Rogne, MD, Carlos Flores, PhD, Jesús Villar, MD, Keith R. Walley, MD, Vincent X. Liu, MD, Alison E. Fohner, PhD, Luca A. Lotta, MD, Christos A. Kyratsous, PhD, Mark W. Sleeman, PhD, Michel Scemama, MD, Richard DelGizzi, MS, Robert Pordy, MD, Julie E. Horowitz, PhD, Aris Baras, MD, Greg S. Martin, MD, Philippe Gabriel Steg, MD, Gregory G. Schwartz, MD, Michael Szarek, PhD, Shaun G. Goodman, MD   +39 more
doaj   +1 more source

Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus:Pooled Analyses from Five Placebo-Controlled Phase 3 Studies [PDF]

, 2018
Introduction: Diabetes mellitus (DM) carries an elevated risk for cardiovascular disease. Here, we assessed alirocumab efficacy and safety in people with/without DM from five placebo-controlled phase 3 studies.
AJ Garber, AL Catapano, American Diabetes Association, BA Ference, CP Cannon, DI Swerdlow, DM Lloyd-Jones, E Climent, EM Roth, GG Schwartz, H Bays, HM Colhoun, HN Ginsberg, J Besseling, JG Robinson, JJ Kastelein, L Ryden, LA Leiter, LA Leiter, LA Lotta, LSF Carvalho de, M Farnier, MF Piepoli, MR Taskinen, MS Sabatine, N Sarwar, N Sattar, ND Wong, RM Krauss, TA Jacobson, U Landmesser   +30 more
core   +3 more sources

Alirocumab in the management of primary hypercholesterolaemia or mixed dyslipidaemia: A budget impact analysis – Italian perspective

Global & Regional Health Technology Assessment, 2018
Recent evidence suggests that adding protein convertase subtilisin/kexin type 9 inhibitors to current lipid-lowering therapies may result in unprecedented reductions in low-density lipoprotein cholesterol.
Alessia Marocco, Sanja Stanisic, Francesca Fanelli, Francesco Damele, Furio Colivicchi   +4 more
doaj   +1 more source

Natriuretic Peptides in the Cardiovascular System. Multifaceted Roles in Physiology, Pathology and Therapeutics [PDF]

, 2019
The natriuretic peptides (NPs) family includes a class of hormones and their receptors needed for the physiological control of cardiovascular functions. The discovery of NPs provided a fundamental contribution into our understanding of the physiological ...
Rubattu, Speranza, Volpe, Massimo
core   +1 more source

Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study

Atherosclerosis Plus, 2021
Background and aims: The benefits of the PCSK9 inhibitors, alirocumab and evolocumab, in lowering LDL-cholesterol and preventing major adverse cardiac events (MACE) have been demonstrated in pivotal clinical trials.
Marina Blanco-Ruiz, Laura Amaya-Pascasio, Reyes de Torres Chacón, María Josefa Álvarez Soria, Antonio Arjona-Padillo, María Magdalena Carrillo Bailén, Rodrigo Milán Pinilla, Irene Pérez Ortega, Belén Sánchez Rodríguez, Luis Andrade Zumárraga, Roberto Valverde Moyano, Manuel Payán Ortiz, Alba María Castillo Fernández, Cristina Del Toro Pérez, Pablo González Bustos, Eduardo Agüera Morales, Purificación Sánchez López, Beatriz Hidalgo Martín, Ricardo Roa Chamorro, Javier Fernández Pérez, María Victoria Mejías Olmedo, Patricia Martínez-Sánchez   +21 more
doaj   +1 more source

Generation of Human Liver Chimeric Mice with Hepatocytes from Familial Hypercholesterolemia Induced Pluripotent Stem Cells [PDF]

, 2017
published_or_final_versio
Au, KW, Bao, X, Chen, S, Cheng, LH, Esteban, MA, Fan, W, Hong, X, Huang, Y, Huang, Z, Hutchins, AP, Ibanez, DP, Lai, KWH, Lai, L, Li, L, Li, Y, Liang, G, Liu, Y, Luo, Z, Qin, B, Siu, DCW, Tian, XY, Tse, HF, Wang, D, Wang, X, WANG, Y, Wei, R, Wong, LY, YANG, J, Zhao, P, Zhong, X, Zhou, T   +30 more
core   +3 more sources